NCT01327495View on ClinicalTrials.gov

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Interventions
OTHER

placebo acyline

Placebo acyline subcutaneous injection every 2 weeks

OTHER

placebo gel

daily placebo testosterone gel applied transdermally x 12 weeks

DRUG

Testosterone 1% gel 1.25 g

testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks

DRUG

Testosterone 1% gel 2.5 g

Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks

DRUG

Testosterone 1% gel 5.0 g

Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks

DRUG

testosterone 1% gel 10 g

Testosterone 1% gel 10 g daily applied transdermally x 12 weeks

DRUG

testosterone 1% gel 15 g

Testosterone 1% gel 15 g daily applied transdermally x 12 weeks

DRUG

Acyline

300 ug/kg subcutaneous injection every 2 weeks

Trial Locations (1)

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

University of Washington

OTHER

NCT01327495 - PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate | Biotech Hunter | Biotech Hunter